| 江 宇,李定彪,刘清华,李振华,石剑林.PD-1及其配体在非小细胞肺癌中的研究现状与展望[J].,2018,(22):4386-4389 |
| PD-1及其配体在非小细胞肺癌中的研究现状与展望 |
| Research Status and Prospect of PD-1 and its Ligand in Non-Small Cell Lung Cancer |
| 投稿时间：2018-01-30 修订日期：2018-02-24 |
| DOI：10.13241/j.cnki.pmb.2018.22.043 |
| 中文关键词: PD-1 PD-L1 非小细胞肺癌 现状 展望 |
| 英文关键词: PD-1 PD-L1 Non small-cell lung cancer Present situation Expectation |
| 基金项目:云南省科技厅基金项目（2012FB103） |
|
| 摘要点击次数: 508 |
| 全文下载次数: 277 |
| 中文摘要: |
| 摘要：肺癌是全球最常见肿瘤之一，其中非小细胞肺癌（NSCLC）约占肺癌的85%。目前肺癌的治疗手段仍然有限，并且晚期肺癌的预后较差，严重影响患者的生命健康。程序性死亡受体1（PD-1）及其配体程序性死亡配体1（PD-L1）属于CD28/B7家族的共刺激分子，可负性调控T细胞免疫功能，使肿瘤细胞免于机体免疫系统的监视和清除。以PD-1/PD-L1单抗为代表的免疫治疗成为继手术治疗、化疗、放疗、分子靶向治疗之后的新焦点，针对PD-1/PD-L1通路的靶向治疗药物纳武单抗（Nivolumab）、派姆单抗（Pembrolizumab）已被食品药品管理局（FDA）批准投入临床使用，且已被国家综合癌症网络（NCCN）推荐为转移性肺癌的一线治疗药物。本文就PD-1/PD-L1的生物学结构及其在NSCLC中的作用机制、靶向药物、研究现状及展望展开综述。 |
| 英文摘要: |
| ABSTRACT: Lung cancer is one of the most common tumors in the world, of which non small-cell lung cancer (NSCLC) accounts for about 85% of lung cancer. At present, the treatment of lung cancer is still limited, and the prognosis of advanced lung cancer is poor,seriously affecting the patient's life and health. Programmed death receptor 1 (PD-1) and its ligand programmed death ligand 1 (PD-L1) belong to the costimulatory molecules of the CD28/B7 family. The negative regulation of T cell immune function, so that tumor cells from the immune system of surveillance and clearance. Immunotherapy with PD-1/PD-L1 monoclonal antibody has become a new focus after surgery, chemotherapy, radiotherapy, and molecular targeted therapy. The PD-1/PD-L1 pathway targeted therapy drugs Wu Na monoclonal antibody (Nivolumab) and paim monoclonal antibody (Pembrolizumab) has been approved for clinical use by the Food and Drug Administration (FDA). It also has been recommended as first-line treatment for metastatic lung cancer by national comprehensive cancer network (NCCN). In this review, we reviewed the biological structure of PD-1/PD-L1 and its mechanism, target drugs, research status and prospect in NSCLC. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
